2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)

P2.09. Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY) - PDF(Slides)

Back to course

Pdf Summary

The study aimed to assess the efficacy of two treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC) based on the clinical profile of the patients. The two strategies compared were osimertinib upfront and a sequence of first generation EGFR TKI followed by osimertinib. The study was conducted as a retrospective multicenter study across 14 centers.<br /><br />The primary endpoint of the study was the progression-free survival of the global strategy, defined as the time between the start of first-line treatment and progression after second-line treatment or death. Subgroup analysis was also conducted based on factors such as tumor burden, presence of central nervous system (CNS) involvement, performance status, and presence of liver metastases.<br /><br />The study found that osimertinib upfront demonstrated prolonged first-line progression-free survival compared to the sequence of first generation TKI followed by osimertinib. This was particularly evident in patients with poor-prognosis EGFR-mutant NSCLC.<br /><br />Further analysis of the study population revealed that the majority of patients received osimertinib as the first-line treatment. The study also showed that patients with CNS involvement had better outcomes with osimertinib upfront compared to the sequence strategy. Similarly, patients with liver metastases and poor performance status also had better outcomes with osimertinib upfront.<br /><br />Overall, the study suggests that osimertinib upfront may be a more effective treatment option for EGFR-mutant NSCLC compared to the sequence strategy. However, further research is needed to validate these findings and to explore the impact of different clinical profiles on treatment outcomes.

Asset Subtitle

Laura Mezquita

Meta Tag

Speaker Laura Mezquita

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR-mutant non-small cell lung cancer

treatment strategies

osimertinib upfront

first generation EGFR TKI

retrospective multicenter study

progression-free survival

tumor burden

central nervous system involvement

liver metastases

poor-prognosis EGFR-mutant NSCLC